Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 525

Sort by

Sort Order Select

Journal Articles

Considerations on the Dose and Schedule of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: Does Dose Matter?

Mark Dalgetty, Jorge Cortes

Blood blood.2024027944.

https://doi.org/10.1182/blood.2024027944

Published: 2025

Journal Articles

Arterio-occlusive events among patients with chronic myeloid leukemia on tyrosine kinase inhibitors

Lukas Veltmaat, Jorge Cortes

Blood (2024) 143 (10): 858–865.

https://doi.org/10.1182/blood.2023022403

Published: 2024

Journal Articles

Asciminib (ASC) Add-on to Imatinib (IMA) Demonstrates Sustained High Rates of Ongoing Therapy and Deep Molecular Responses (DMRs) with Prolonged Follow-up in the ASC4MORE Study

Timothy P Hughes, Giuseppe Saglio, Jan Geissler, Dong-Wook Kim, Elza Lomaia, Jiri Mayer, Anna Turkina, Shruti Kapoor, Ana Paula Torres Cardoso, Jomy Jose, Monali Sura, Jorge Cortes

Blood (2023) 142 (Supplement 1): 866.

https://doi.org/10.1182/blood-2023-182100

Published: 2023

Journal Articles

With up to 8 Years of Therapy, Asciminib (ASC) Monotherapy Demonstrated Continued Favorable Efficacy, Safety, and Tolerability in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) without the T315I Mutation: Final Results from the Phase 1 X2101 Study

Blood (2023) 142 (Supplement 1): 450.

https://doi.org/10.1182/blood-2023-187322

Published: 2023

Journal Articles

Phase I Study of the T-Cell Receptor-like Antibody, Hu8F4 in Patients with Relapsed and Refractory Myeloid Malignancies

Blood (2023) 142 (Supplement 1): 1545.

https://doi.org/10.1182/blood-2023-189966

Published: 2023

Journal Articles

Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or Venetoclax

Jorge Cortes, Joseph Jurcic, Maria R. Baer, William Blum, P. Brent Ferrell, Jr., Brian A. Jonas, Sangmin Lee, Alice Mims, Shyam Ajay Patel, Gary J. Schiller, Jay Yang, Justin M. Watts

Blood (2023) 142 (Supplement 1): 2888.

https://doi.org/10.1182/blood-2023-187861

Published: 2023

Journal Articles

Eliminating Racial Disparities Among Transplant Patients in Multiple Myeloma after Referral to a Tertiary Center

Shreya Desai, Meaghan Standridge, Danielle Bradshaw, Mohammad Mian, Ayushi Chauhan, Amany R. Keruakous, Locke Johnson Bryan, Jorge Cortes, Anand Jillella, Vamsi K. Kota

Blood (2023) 142 (Supplement 1): 6659.

https://doi.org/10.1182/blood-2023-190828

Published: 2023

Journal Articles

Disparities in Phase 3 Leukemia Trials from the Last Decade: A Long Way to Go

Andres Noyola-Perez, Alejandra J. Osuna-Corrales, Manali I. Patel, Jorge Cortes, Lillian Sung, Juan C. Angulo-Lozano, Perla R. Colunga-Pedraza, David Gomez-Almaguer, Guillermo José Ruiz-Arguelles, Andres Gomez-De Leon

Blood (2023) 142 (Supplement 1): 494.

https://doi.org/10.1182/blood-2023-189576

Published: 2023

Journal Articles

Asciminib (ASC) in Combination with Imatinib (IMA), Nilotinib (NIL), or Dasatinib (DAS) May be a Potential Treatment (Tx) Option in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase or Accelerated Phase (Ph+ CML-CP/AP): Final Results from the Asciminib Phase 1 Study

Jorge Cortes, Fabian Lang, Delphine Rea, Andreas Hochhaus, Massimo Breccia, Yeow Tee Goh, Michael C. Heinrich, Timothy P Hughes, Jeroen J.W.M. Janssen, Philipp le Coutre, Hironobu Minami, Koji Sasaki, Daniel J. DeAngelo, Gessami Sanchez-Olle, Nathalie Pognan, Jomy Jose, Matthias Hoch, Michael Mauro

Blood (2023) 142 (Supplement 1): 868.

https://doi.org/10.1182/blood-2023-189270

Published: 2023

Journal Articles

Long-Term Results from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Blood (2023) 142 (Supplement 1): 3164.

https://doi.org/10.1182/blood-2023-178790

Published: 2023

Journal Articles

Drug Development for Leukemia : Comprehensive Analysis of Clinical Trial Success Rates Presented at the American Society Hematology (ASH) Annual Meetings

Kellen Tjioe, Marisol Miranda-Galvis, Thalyta Medeiros, Kenza Mamouni, Brenda Santellano, Claudia Guillen, Jorge Cortes

Blood (2023) 142 (Supplement 1): 3802.

https://doi.org/10.1182/blood-2023-182247

Published: 2023

Journal Articles

Hidac Consolidation Cycles May Impede Stem Cell Transplant Planning for High-Risk Acute Myeloid Leukemia Patients

Michael Stokes, Danielle Bradshaw, Yazmin Reategui, Isabela Pavkov, Mohammad Mian, Locke Johnson Bryan, Amany R. Keruakous, Ayushi Chauhan, Jorge Cortes, Anand Jillella, Vamsi K. Kota

Blood (2023) 142 (Supplement 1): 5854.

https://doi.org/10.1182/blood-2023-191220

Published: 2023

Journal Articles

Quantum-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3 -ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed through Induction (IND) and Consolidation (CONS) Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (nd) FLT3 -ITD+ AML Patients (pts)

Blood (2023) 142 (Supplement 1): 832.

https://doi.org/10.1182/blood-2023-186785

Published: 2023

Journal Articles

A Highly Successful Model to Decrease Racial Disparities and Increase Access to Autologous Transplants Among African Americans with Multiple Myeloma - Outreach and Satellite Transplant Clinics

Anand Jillella, Danielle Bradshaw, Mohammad Mian, Jorge Cortes, Amany R. Keruakous, Ayushi Chauhan, Locke Johnson Bryan, Molly Denlinger, Vamsi K. Kota

Blood (2023) 142 (Supplement 1): 4969.

https://doi.org/10.1182/blood-2023-191069

Published: 2023

Journal Articles

Patient-Reported Outcomes in Acute Myeloid Leukemia Patients with FLT3 -ITD Mutation Receiving Quizartinib Vs. Standard Chemotherapy: Results from the Quantum-First Trial

Esther Natalie Oliva, Sudhir Unni, Francesco Cottone, Rohan Vashi, Xiaocong Li, Jorge Cortes, Mikkael A. Sekeres

Blood (2023) 142 (Supplement 1): 918.

https://doi.org/10.1182/blood-2023-189035

Published: 2023

Journal Articles

Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Follow-up from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population

Blood (2023) 142 (Supplement 1): 4536.

https://doi.org/10.1182/blood-2023-186854

Published: 2023

Journal Articles

Therapy Related Multiple Myeloma: A Distinct Entity

Meaghan Standridge, Shreya Desai, Sujith Abbagoni, Sabrina Matosz, Danielle Bradshaw, Mohammad Mian, Mohommed Syam, Vamsi K. Kota, Jorge Cortes, Amany R. Keruakous, Ayushi Chauhan, Locke Johnson Bryan, Anand Jillella

Blood (2023) 142 (Supplement 1): 6657.

https://doi.org/10.1182/blood-2023-190298

Published: 2023

Journal Articles

Outcomes of Regimented Weight Monitoring on Morbidity and Mortality during AML Induction

Anvay Shah, Nabil Ghani, Danielle Bradshaw, Anand Jillella, Vamsi K. Kota, Jorge Cortes, Mark Dalgetty, Zachery Branham, Sandeep Yerraguntla, Locke Johnson Bryan, Amany R. Keruakous, Ayushi Chauhan

Blood (2023) 142 (Supplement 1): 5875.

https://doi.org/10.1182/blood-2023-190979

Published: 2023

Journal Articles

Outcomes in Acute Lymphoid Leukemia Patients with Incomplete Hyper-CVAD Cycles

Sabrina Matosz, Meaghan Standridge, Danielle Bradshaw, Amany R. Keruakous, Jorge Cortes, Mohammad Mian, Locke Johnson Bryan, Anand Jillella, Ayushi Chauhan, Vamsi K. Kota

Blood (2023) 142 (Supplement 1): 5887.

https://doi.org/10.1182/blood-2023-190334

Published: 2023

Journal Articles

Prephase Cyclophosphamide: An Advantageous Bridge to Definitive Therapy

Meaghan Standridge, Shreya Desai, Sandeep Yerraguntla, Danielle Bradshaw, Mohammad Mian, Vamsi K. Kota, Anand Jillella, Jorge Cortes, Ayushi Chauhan, Amany R. Keruakous, Locke Johnson Bryan

Blood (2023) 142 (Supplement 1): 6316.

https://doi.org/10.1182/blood-2023-190805

Published: 2023

NARROW

Considerations on the Dose and Schedule of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: Does Dose Matter?

Arterio-occlusive events among patients with chronic myeloid leukemia on tyrosine kinase inhibitors

Asciminib (ASC) Add-on to Imatinib (IMA) Demonstrates Sustained High Rates of Ongoing Therapy and Deep Molecular Responses (DMRs) with Prolonged Follow-up in the ASC4MORE Study

Phase I Study of the T-Cell Receptor-like Antibody, Hu8F4 in Patients with Relapsed and Refractory Myeloid Malignancies

Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or Venetoclax

Eliminating Racial Disparities Among Transplant Patients in Multiple Myeloma after Referral to a Tertiary Center

Disparities in Phase 3 Leukemia Trials from the Last Decade: A Long Way to Go

Long-Term Results from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Drug Development for Leukemia : Comprehensive Analysis of Clinical Trial Success Rates Presented at the American Society Hematology (ASH) Annual Meetings

Hidac Consolidation Cycles May Impede Stem Cell Transplant Planning for High-Risk Acute Myeloid Leukemia Patients

A Highly Successful Model to Decrease Racial Disparities and Increase Access to Autologous Transplants Among African Americans with Multiple Myeloma - Outreach and Satellite Transplant Clinics

Patient-Reported Outcomes in Acute Myeloid Leukemia Patients with FLT3 -ITD Mutation Receiving Quizartinib Vs. Standard Chemotherapy: Results from the Quantum-First Trial

Therapy Related Multiple Myeloma: A Distinct Entity

Outcomes of Regimented Weight Monitoring on Morbidity and Mortality during AML Induction

Outcomes in Acute Lymphoid Leukemia Patients with Incomplete Hyper-CVAD Cycles

Prephase Cyclophosphamide: An Advantageous Bridge to Definitive Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only